JNCCN 360 - Non–Small Cell Lung Cancer - News

Advertisement

Advertisement

News

ADAURA Update: Adjuvant Osimertinib Maintains Overall Survival Benefit at 8 Years in EGFR-Mutated NSCLC

Amivantamab and Chemotherapy Prolong OS in Previously Untreated EGFR ex20ins NSCLC

Early Trial Supports Phase III Evaluation of Daraxonrasib in RAS-Mutant NSCLC

FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous NSCLC

Does the Timing of Immunotherapy Administration Influence Survival Outcomes in Advanced Cancers?

Guideline-Concordant Lymph Node Sampling Does Not Increase Complications After NSCLC Resection

Zidesamtinib Approved for Second-Line Treatment of ROS1-Positive NSCLC

ASCO 2026: HARMONi-6 Meets Overall Survival Endpoint in Advanced Squamous NSCLC

ASCO 2026: Adjuvant Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

AACR 2026: Zoldonrasib Shows Promising Responses in KRAS G12D–Mutated Lung Cancer

Predicting Overall Survival in Metastatic NSCLC: Daily Step Count vs ECOG Performance Status

Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved